Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 118 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M4PSWWtqdmG|ZTDBd5NigQ>? NUjm[|VyOjRiaB?= MVHJcohq[mm2aX;uJI9nKEOGS{SgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDSZkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECyJO69VQ>? MVeyOFY1OTFyMx?=
COLO205 NEPtfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PxelczKGh? NUnmN3pqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1? NF\iflAzPDZ2MUGwNy=>
U937 NWfLeIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnWNos4OiCq MkDMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> MkTWNlQ3PDFzMEO=
MOLM13 M4rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv3O|IhcA>? MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN MoXpNlQ3PDFzMEO=
MOLM13 M{Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fQdlczKGh? MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NYD3ZpRVOjR4NEGxNFM>
MDA-MB-435 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\uNlQhcA>? NWm2c45EUUN3ME2wMlE3KM7:TR?= NHK3SngyPThyMUizNS=>
K562 Ml\2R5l1d3SxeHnjJGF{e2G7 MkXyPVYhcA>? NEHBUmlFVVOR NH7y[llKSzVyPUKg{txO MnnsNlQ1OTd3Nk[=
DU145 NHXmWIhEgXSxdH;4bYMhSXO|YYm= NG\FcWU6PiCq MV3EUXNQ MmfuTWM2OD15LkWg{txO MVKyOFQyPzV4Nh?=
MDA-MB-231 M{HBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\uNUDPxE1? MU[yOEBp M{\qZWROW09? MYrD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= M4f5NFI1PDF5NU[2
MCF7 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPHbZl3OSEQvF2= M4fuOFI1KGh? M2LPSWROW09? M4noeWNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NIfCepkzPDRzN{W2Oi=>
MCF7 M1HX[mtqdmG|ZTDBd5NigQ>? NGHlTYQ2KM7:TR?= MX6yOEBp NVnaOVhsTE2VTx?= MYXJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET|Qw[3mlbHnuSFEh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy MkO2NlQ1OTd3Nk[=
MDA-MB-231 MkftT4lv[XOnIFHzd4F6 MWG1JO69VQ>? MXKyOEBp NFXwZYVFVVOR MlL1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= NUntXVNnOjR2MUe1OlY>
MDA-MB-231 MV\GeY5kfGmxbjDBd5NigQ>? M4\1SFEuOTBizszN NGnjXlczPCCq M{XuO2ROW09? MUfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? NGK4[3UzPDRzN{W2Oi=>
MCF7 NYfMfYZTTnWwY4Tpc44hSXO|YYm= NWfiVJNqOS1zMDFOwG0> NYLpcYJ[OjRiaB?= MlLWSG1UVw>? M1XUfoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= MV2yOFQyPzV4Nh?=
MDA-MB-231 NX:0UVFUTnWwY4Tpc44hSXO|YYm= NXfXNG9vOC53LUGg{txO MnXBOFghcA>? MkDCSG1UVw>? MmDTbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> NH3DSnQzPDRzN{W2Oi=>
MCF7 NE[0S4JHfW6ldHnvckBCe3OjeR?= M4H6S|AvPS1zIN88US=> MVK0PEBp NFL3OppFVVOR M3PKdohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm NI\UZYUzPDRzN{W2Oi=>
697 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PcIpKSzVyPUG0PE4{QCCwTR?= M1rzVnNCVkeHUh?=
P12-ICHIKAWA MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTl4LkC0JI5O MV7TRW5ITVJ?
NB69 NXq0WGNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sUWlEPTB;MU[xMlghdk1? NUi3V2huW0GQR1XS
EoL-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\IUmlEPTB;MUi3MlI3KG6P NWTXb41kW0GQR1XS
BHT-101 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF7OD6yOUBvVQ>? NUfycmJ5W0GQR1XS
SK-NEP-1 NYL5bVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULhWmZDUUN3ME2yNlAvODJibl2= MmjrV2FPT0WU
MHH-NB-11 NXXwZ3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzycJdOUUN3ME2yNlAvOTlibl2= MWnTRW5ITVJ?
AsPC-1 NHPVTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELDSFlKSzVyPUK1Nk42OyCwTR?= NFXLN2ZUSU6JRWK=
ES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XufmlEPTB;MkW2MlI2KG6P MXzTRW5ITVJ?
LAMA-84 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj6TWM2OD1{NUiuNVkhdk1? MmO3V2FPT0WU
MOLT-16 M4PVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[4XZNKSzVyPUK1PE41QSCwTR?= MVnTRW5ITVJ?
ES7 M1PSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj2TWM2OD1{N{OuNFkhdk1? NIjMNXJUSU6JRWK=
KY821 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFN4s{UUN3ME2zNVQvOSCwTR?= MmfHV2FPT0WU
RT-112 NWHsbnNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN{MT6wOUBvVQ>? NVTjXGdCW0GQR1XS
HL-60 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr5TWM2OD1|NECuOlYhdk1? MmfFV2FPT0WU
MOLT-4 NYPae2c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS0TWM2OD1|NEWuNVMhdk1? MmjIV2FPT0WU
KARPAS-45 NEPHZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXLT4d1UUN3ME2zO|YvOTZibl2= NHrUc4hUSU6JRWK=
SK-N-AS Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LxXmlEPTB;M{i3Mlg{KG6P M2jnVnNCVkeHUh?=
CTB-1 NFe3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRyNT6wNkBvVQ>? MWrTRW5ITVJ?
NKM-1 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH3clBpUUN3ME20NVEvQDlibl2= NHP1bI1USU6JRWK=
HTC-C3 NGHS[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5fWlEPTB;NEOyMlk2KG6P MWPTRW5ITVJ?
BE-13 NX;nZ3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmzbmJKSzVyPUS0OE4zPyCwTR?= NIrqO4NUSU6JRWK=
KOSC-2 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITWeGlKSzVyPUS2Ok46KG6P NX\jendnW0GQR1XS
NB14 NHfybmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrUW5hKSzVyPUS4N{42QCCwTR?= MV;TRW5ITVJ?
CAL-27 M4PFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKwTWM2OD12OUSuOVkhdk1? MoTvV2FPT0WU
H9 M{DGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzSTWM2OD12OUWuOFMhdk1? MmHPV2FPT0WU
RS4-11 M3Kw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fKTmlEPTB;NUC0Mlc{KG6P Ml\yV2FPT0WU
PA-1 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD13MEmuPFYhdk1? NInVdJhUSU6JRWK=
MV-4-11 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL4cJBKSzVyPUWxN{45PSCwTR?= NXPuSZZxW0GQR1XS
OS-RC-2 M2\kXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjKe5JKSzVyPUWyNU43OiCwTR?= NG\aSIpUSU6JRWK=
RPMI-8226 NYT1WVR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTV{Nj64OkBvVQ>? MUHTRW5ITVJ?
HGC-27 NGj3RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jzd2lEPTB;NU[0Mlk6KG6P MXLTRW5ITVJ?
CHP-212 M1e3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2TWM2OD13OUOuOVkhdk1? NYf1b5FOW0GQR1XS
NB10 NHPLZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv3TWM2OD13OUmuNVghdk1? M1HIOHNCVkeHUh?=
HH NITmeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTV7OT60N{BvVQ>? MkXHV2FPT0WU
EW-16 M2PKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XUTWlEPTB;NkCzMlUzKG6P MmnMV2FPT0WU
ES8 M3\Vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZyNT6yNUBvVQ>? NXzoT4ZOW0GQR1XS
HAL-01 NV6xO3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqwXIJKSzVyPU[wOU43PyCwTR?= NXXrPJgyW0GQR1XS
A204 M2nrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fXW2lEPTB;NkOzMlkyKG6P MW\TRW5ITVJ?
MHH-PREB-1 NEjiWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5dVdFUUN3ME22N|YvQTlibl2= NWHWcGozW0GQR1XS
EM-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZ3MD62OEBvVQ>? M3fMbHNCVkeHUh?=
BV-173 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK0eGZOUUN3ME22OVIvPDhibl2= MXnTRW5ITVJ?
ONS-76 NELyeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG1TWM2OD14N{euPFIhdk1? MXTTRW5ITVJ?
KM-H2 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTZ7NT61OEBvVQ>? NUfGTJN1W0GQR1XS
D-263MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD15MUeuNVIhdk1? M2nRb3NCVkeHUh?=
ES3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTd{OD65N{BvVQ>? MYnTRW5ITVJ?
VA-ES-BJ NUjF[XQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHpcGRKSzVyPUezNk4zPyCwTR?= NVPmTGdvW0GQR1XS
NBsusSR MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn6TGQxUUN3ME23OFIvQTlibl2= MWPTRW5ITVJ?
NCI-H520 M1LXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\1TWM2OD15NE[uOVIhdk1? NXL6[nVoW0GQR1XS
ES5 M1Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXoTWM2OD15NUKuPEBvVQ>? NHTqRoVUSU6JRWK=
T-24 NYXVPVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LBSmlEPTB;N{e4MlcyKG6P NVXDUHBWW0GQR1XS
SW962 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRThyOD62N{BvVQ>? MYTTRW5ITVJ?
EW-3 M3vlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThyOD63OkBvVQ>? NYf2cndRW0GQR1XS
RXF393 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;wTWM2OD16MUKuO|khdk1? MkLyV2FPT0WU
U251 M4HydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLNU5pKSzVyPUixN{45QCCwTR?= Mm\OV2FPT0WU
CAMA-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLzcnZKSzVyPUizN{46PCCwTR?= NIPKUnNUSU6JRWK=
JVM-3 M{\Mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH0TWM2OD16NUGuO|ghdk1? NHzuT2xUSU6JRWK=
COLO-800 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T0bGlEPTB;OEm3Mlc5KG6P NXn6TZFHW0GQR1XS
OVCAR-5 NEK0bFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTlyMD6xJI5O M2fqPXNCVkeHUh?=
LB1047-RCC NWKxN3Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTl{Nz61OkBvVQ>? NIHwS|lUSU6JRWK=
SW954 NHXsbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXMTWM2OD17MkmuOFEhdk1? NVnTUnNQW0GQR1XS
J-RT3-T3-5 M1fH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;sOGlEPTB;OUO2MlA3KG6P MnzDV2FPT0WU
Mewo MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vn[WlEPTB;OUO2MlYhdk1? NFTUfVRUSU6JRWK=
NCI-H1770 NUP3bYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTl2MD61OUBvVQ>? M{TXU3NCVkeHUh?=
HO-1-N-1 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O4Z2lEPTB;OU[yMlgyKG6P NWjSZVJLW0GQR1XS
HSC-3 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17yXWlEPTB;OU[2MlQ5KG6P NVvPVXVLW0GQR1XS
TYK-nu NFPMbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTl7OD6yOUBvVQ>? MYLTRW5ITVJ?
KYSE-150 M1u2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TDc2lEPTB;MT6wNFA4PiEQvF2= NWTBV5R6W0GQR1XS
SN12C NWrCTY4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHq[29KSzVyPUGuNFA5PzVizszN M2PY[XNCVkeHUh?=
MOLT-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HH[mlEPTB;MT6wNVQzOSEQvF2= Ml:3V2FPT0WU
TE-11 NF;XU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\KR2lEPTB;MT6wOFgyOiEQvF2= NUG1RW9qW0GQR1XS
DB NFrzV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:3WWlEPTB;MT6wO|I4OyEQvF2= M3rTcHNCVkeHUh?=
CAL-39 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMEe1NlIh|ryP MXfTRW5ITVJ?
A3-KAW NX35bopQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTFwMEi0NFgh|ryP M3TRd3NCVkeHUh?=
CHP-134 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\MTYJKSzVyPUGuNVE5ODdizszN M{P2XHNCVkeHUh?=
TGW NGrUR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFwMUKzPVUh|ryP MYDTRW5ITVJ?
QIMR-WIL M4P1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LVXmlEPTB;MT6xN|E{PCEQvF2= MnfEV2FPT0WU
NCI-SNU-1 NWnhfWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\CfmlEPTB;MT6xOlM2PCEQvF2= MYjTRW5ITVJ?
CGTH-W-1 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfqSZEyUUN3ME2xMlE4OTh4IN88US=> NIXVPWRUSU6JRWK=
MHH-ES-1 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TafGlEPTB;MT6xO|k5PiEQvF2= NEHCSY9USU6JRWK=
LB2241-RCC NWLVZXFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQWGlEPTB;MT6xPFYzKM7:TR?= M{foW3NCVkeHUh?=
ML-2 M3jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPMTWM2OD1zLkKwO|M1KM7:TR?= MVnTRW5ITVJ?
COR-L23 M1;XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7RVYRKSzVyPUGuNlI6OzNizszN NGTReWRUSU6JRWK=
BFTC-905 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDLe5NKSzVyPUGuNlQzPjdizszN M134eXNCVkeHUh?=
Hs-578-T NVvkOHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrMZ4dUUUN3ME2xMlI2QDF5IN88US=> M1jOfHNCVkeHUh?=
KG-1 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMk[2PFYh|ryP NIrlUmFUSU6JRWK=
HEL NYHVV|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS4NWZZUUN3ME2xMlI6OzN6IN88US=> MVjTRW5ITVJ?
A549 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrOTWM2OD1zLkK5N|k6KM7:TR?= M3OxSHNCVkeHUh?=
COLO-741 NWHsdphnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\xTWM2OD1zLkOyNFg6KM7:TR?= MW\TRW5ITVJ?
PC-3 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO0ZmtKSzVyPUGuN|UzOjFizszN MoTKV2FPT0WU
HOS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwM{WyPVYh|ryP NWrCUZJuW0GQR1XS
HT-1080 NXHNfGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwM{e1NVkh|ryP M2HEZXNCVkeHUh?=
TE-8 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHZWxKSzVyPUGuOFE4PzRizszN NH\DO4RUSU6JRWK=
BHY MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\STZhIUUN3ME2xMlQ3QTJ|IN88US=> NHPJPFFUSU6JRWK=
BB65-RCC NEHIR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLDTWM2OD1zLkWwOVI5KM7:TR?= M4rudXNCVkeHUh?=
HN NHHiPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2bmlEPTB;MT61OFA4OSEQvF2= MULTRW5ITVJ?
NCI-H441 NITxbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnZO|VKSzVyPUGuOVQ6ODdizszN NYWxcZBnW0GQR1XS
RPMI-8866 NFT3XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfPeoozUUN3ME2xMlU5PTB5IN88US=> NUjBOY5FW0GQR1XS
CAL-62 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwNkC4OlIh|ryP M4\PSXNCVkeHUh?=
MG-63 NIfzWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwNkG4NVMh|ryP NXLkUZJWW0GQR1XS
SK-LU-1 M1HzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1joNGlEPTB;MT62NlE2OiEQvF2= NEDycZpUSU6JRWK=
BCPAP MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n5c2lEPTB;MT62OlQ2PyEQvF2= NXnqXZFzW0GQR1XS
22RV1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPjTWM2OD1zLk[3PFQ{KM7:TR?= NVjWPXJSW0GQR1XS
T47D MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDkT3duUUN3ME2xMlY5ODZzIN88US=> NEPYdW1USU6JRWK=
MSTO-211H NHS2UWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i2TmlEPTB;MT62PVYxOyEQvF2= NEP1eYdUSU6JRWK=
DEL NVXtNnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\LeY5KSzVyPUGuO|AzPzNizszN MmfLV2FPT0WU
H4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\GTWM2OD1zLkezNlEzKM7:TR?= NH\lU5pUSU6JRWK=
CAL-51 NEfnSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELTfVBKSzVyPUGuO|Q5PTVizszN NEW5dGJUSU6JRWK=
ABC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f5dWlEPTB;MT63PFU5OiEQvF2= M2XBfXNCVkeHUh?=
MZ2-MEL NXfreVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jFV2lEPTB;MT63PVU1OiEQvF2= M4LLd3NCVkeHUh?=
YKG-1 NWO4emJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnTfmNNUUN3ME2xMlgyODZzIN88US=> M4rEW3NCVkeHUh?=
KM12 NFfFVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\FTWM2OD1zLkixOlAzKM7:TR?= NUjlZ|FDW0GQR1XS
L-363 NXXrcmtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\OV|JRUUN3ME2xMlg4PDF{IN88US=> M1TmSHNCVkeHUh?=
KU812 M{T1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPHNYpLUUN3ME2xMlg6Ojh{IN88US=> MlrvV2FPT0WU
LOXIMVI NWP1XYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrlZVdIUUN3ME2xMlkyOjJ6IN88US=> NVfFR3hPW0GQR1XS
G-401 Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi3N4lZUUN3ME2xMlkzPDJ6IN88US=> NYrkXVZqW0GQR1XS
SW780 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XRNGlEPTB;MT65OlI1PiEQvF2= Mlf2V2FPT0WU
SW872 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jHZ2lEPTB;MT65PFM{KM7:TR?= NGjHcGRUSU6JRWK=
NB7 NX;VSGY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvQNW5mUUN3ME2xMlk6OzJ|IN88US=> MlrFV2FPT0WU
T98G MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwMEC2OlYh|ryP MVTTRW5ITVJ?
SW1710 NVvxXZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwME[5OFUh|ryP M2nLXnNCVkeHUh?=
NCI-H1573 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHWdlZKSzVyPUKuNFczQThizszN NWHmUVlLW0GQR1XS
KE-37 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn65TWM2OD1{LkC4PVUyKM7:TR?= NFXMcWhUSU6JRWK=
786-0 NWTWOnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnOdFVKSzVyPUKuNVU1OzlizszN NYXnemdGW0GQR1XS
SAS NUT4ZpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\G[3cxUUN3ME2yMlIxOzd2IN88US=> MVXTRW5ITVJ?
CAL-54 NF7XTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwMkC0NVMh|ryP MUPTRW5ITVJ?
SF268 M2\qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLrd|RuUUN3ME2yMlI{OTJ{IN88US=> MX3TRW5ITVJ?
SW620 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HLUWlEPTB;Mj6yOlE3QSEQvF2= NEfxcVBUSU6JRWK=
MN-60 NH3SNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nwdWlEPTB;Mj6zNVA3KM7:TR?= M3\vTnNCVkeHUh?=
EFO-27 NYrOOWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeycIpKSzVyPUKuN|IxPThizszN Mom5V2FPT0WU
NCI-H747 NHntOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXrTWM2OD1{LkOyNVk6KM7:TR?= MXLTRW5ITVJ?
HCC2218 M1HucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwM{WzO|Qh|ryP M4\0d3NCVkeHUh?=
MIA-PaCa-2 MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DQVGlEPTB;Mj6zOlQ{PyEQvF2= M{iw[nNCVkeHUh?=
SJSA-1 NYfYS3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT4VYxKSzVyPUKuN|c4QTZizszN NEWycVBUSU6JRWK=
RKO Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrCcGJKSzVyPUKuN|g1QTZizszN M{WwN3NCVkeHUh?=
NB6 M1z3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PvOGlEPTB;Mj60NFM4PCEQvF2= NETLbmVUSU6JRWK=
ES4 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT2OJZOUUN3ME2yMlQ2PDJ{IN88US=> NH[xTIRUSU6JRWK=
EGI-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrrV3lrUUN3ME2yMlQ3QDh|IN88US=> NEXFcJNUSU6JRWK=
CTV-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwNUK3O|Mh|ryP NVLiWodsW0GQR1XS
NCI-H1355 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJwNUW5OVEh|ryP NHvke5pUSU6JRWK=
GT3TKB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwNUmxPVkh|ryP NF;FN3lUSU6JRWK=
SK-HEP-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD1{LkW5NlY3KM7:TR?= NV3xdXdPW0GQR1XS
GAMG MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu4fHpKSzVyPUKuOVk{QTRizszN NGHlOohUSU6JRWK=
SK-MES-1 M{LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT0NoVbUUN3ME2yMlYyQDB|IN88US=> NGKzb|lUSU6JRWK=
RO82-W-1 M4r0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\jZWdKSzVyPUKuOlIxPTdizszN NVnleo53W0GQR1XS
ECC10 M{jodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTJwN{CyNFYh|ryP NHT5b3hUSU6JRWK=
MCF7 NHz2UZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwN{G0OlQh|ryP MmW1V2FPT0WU
D-283MED Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPmeIlKSzVyPUKuO|I1OyEQvF2= MlXlV2FPT0WU
RPMI-7951 NFT0WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\BTWM2OD1{Lke1Olk1KM7:TR?= M{\aRXNCVkeHUh?=
Ramos-2G6-4C10 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0ZXVKSzVyPUKuO|cxQTlizszN MkX3V2FPT0WU
KGN MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rIZWlEPTB;Mj64NVg5PCEQvF2= MVjTRW5ITVJ?
NUGC-3 NY[1XpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXJTWM2OD1{LkiyOVA2KM7:TR?= Mlq1V2FPT0WU
NCI-H292 NIPvTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq4O|VKSzVyPUKuPFUxPTNizszN MkLXV2FPT0WU
Becker NYnXcJVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfM[|RyUUN3ME2yMlk2QDN{IN88US=> M4OyZnNCVkeHUh?=
NCI-H1299 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT0TWM2OD1|LkC1NlY{KM7:TR?= NEjId41USU6JRWK=
ETK-1 M1X3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjzfXRuUUN3ME2zMlA2PDNizszN MkDYV2FPT0WU
TK10 NFGz[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7TbHpnUUN3ME2zMlIxOTZ3IN88US=> NYDiPYJtW0GQR1XS
VMRC-RCZ M4XTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS0TWM2OD1|LkO2OFg5KM7:TR?= NYDsb2VmW0GQR1XS
YH-13 NIG3UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTJfFlGUUN3ME2zMlQ1ODd7IN88US=> MnOzV2FPT0WU
DU-145 M3TUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0SGlEPTB;Mz60OlI3QSEQvF2= NXrZb4lrW0GQR1XS
SW1088 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPt[HFKSzVyPUOuOFc1PyEQvF2= MX\TRW5ITVJ?
HOP-92 M{H0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorTTWM2OD1|LkWwN|QzKM7:TR?= MljzV2FPT0WU
KP-N-YS M3vHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LlNGlEPTB;Mz62NlE{QSEQvF2= NWK1fpFpW0GQR1XS
NCI-H460 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF65bWVKSzVyPUOuOlY4OyEQvF2= NEnrN2dUSU6JRWK=
U-2-OS Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jFO2lEPTB;Mz63NlU{PSEQvF2= NGfVS3hUSU6JRWK=
A101D Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaNG52UUN3ME2zMlc3QTN4IN88US=> NITXfFRUSU6JRWK=
MDA-MB-231 NYrpVnY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPlT5JVUUN3ME2zMlgyQTVzIN88US=> M2jGU3NCVkeHUh?=
IST-MES1 M3e4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XKS2lEPTB;Mz64N|Ih|ryP NVrFW2FIW0GQR1XS
COR-L105 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHFTWM2OD12LkCxPEDPxE1? MWHTRW5ITVJ?
NCI-H1437 M2PpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTRwMEKzNFIh|ryP NYjyT4ZGW0GQR1XS
CAL-85-1 M2TZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnGwTWM2OD12LkCyOFYyKM7:TR?= NEnsc3dUSU6JRWK=
MZ1-PC M3PJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPFPIVZUUN3ME20MlE5PTV4IN88US=> NHTtfFdUSU6JRWK=
VM-CUB-1 NH7mV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHPXpBrUUN3ME20MlMyOjh2IN88US=> MYrTRW5ITVJ?
CHL-1 NXLv[HlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\UdGpKSzVyPUSuN|IyPjlizszN NHXGfIZUSU6JRWK=
MDA-MB-361 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTSTWM2OD12LkOzNVU{KM7:TR?= NEGxb4dUSU6JRWK=
NCI-H661 NH:3bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nreGlEPTB;ND61NFA6OiEQvF2= MlKwV2FPT0WU
EW-11 M{DJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwNUKyN|Eh|ryP MoTqV2FPT0WU
BEN NGLLSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n2WGlEPTB;ND61NlgyPSEQvF2= MkLwV2FPT0WU
BFTC-909 M4LzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD12LkW2Nlc2KM7:TR?= M4fnR3NCVkeHUh?=
NCI-H2087 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTXHRKSzVyPUSuOVgyPjRizszN MVnTRW5ITVJ?
RVH-421 NFrIVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLGTWM2OD12Lk[2Olkh|ryP NX\jXIJlW0GQR1XS
P30-OHK MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLjW25KSzVyPUSuOlgxODhizszN NYHzOVBqW0GQR1XS
NCI-H28 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e3WGlEPTB;ND64NVY3OSEQvF2= M2LvPXNCVkeHUh?=
ES6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH3TWM2OD12LkizNFE3KM7:TR?= NGe3Z5dUSU6JRWK=
769-P NEjjUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPWepBKSzVyPUSuPFU6OjZizszN MYjTRW5ITVJ?
OE33 NVi3NYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3W0e2lEPTB;ND64PFE3OSEQvF2= NHPrNJpUSU6JRWK=
SW982 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\nW2RKSzVyPUSuPVUxPjFizszN M1vvdnNCVkeHUh?=
A388 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH3TWM2OD13LkCyPVg{KM7:TR?= NVPpe2pFW0GQR1XS
TI-73 NFzQOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjtVHVyUUN3ME21MlA3OTl2IN88US=> MXnTRW5ITVJ?
HCT-116 NGrncnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwMEm4PFkh|ryP M2PsdnNCVkeHUh?=
HuP-T3 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVwMUi3NFkh|ryP MmfSV2FPT0WU
G-402 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFru[oZKSzVyPUWuNVk1OTZizszN MXfTRW5ITVJ?
NCI-H1792 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKzdIlKSzVyPUWuNlQ3OjJizszN MYHTRW5ITVJ?
NCI-H209 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r4WGlEPTB;NT6yOVk1OiEQvF2= NHnqeJhUSU6JRWK=
NCI-H1650 NG\ESYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVwM{C2N|Qh|ryP MXvTRW5ITVJ?
LCLC-97TM1 M1r5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iyS2lEPTB;NT6zNVgxQCEQvF2= MWTTRW5ITVJ?
S-117 M37MOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXtdoZKSzVyPUWuN|Y6PzZizszN NFq5SlRUSU6JRWK=
GI-ME-N NYHFSpB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDIO|BbUUN3ME21MlM6PjhzIN88US=> NXfScXROW0GQR1XS
NCI-H2122 NEDXOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nVTWlEPTB;NT60PVM6PyEQvF2= NH7VU4tUSU6JRWK=
NCI-H1793 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TpTGlEPTB;NT62O|U6OyEQvF2= MknRV2FPT0WU
C2BBe1 M1XzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTVwN{CwPFgh|ryP NUnifpV5W0GQR1XS
TE-12 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzTW2JKSzVyPUWuPFA2PTZizszN M3;zPHNCVkeHUh?=
LCLC-103H MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPCTWM2OD13LkmxO{DPxE1? NFewXlNUSU6JRWK=
A673 NXrxOm81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS3TWM2OD13LkmxPVMzKM7:TR?= MnHQV2FPT0WU
BB30-HNC MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTVwOUizOkDPxE1? MXjTRW5ITVJ?
SF295 NWH2NHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O0N2lEPTB;Nj6wNFQzOiEQvF2= NIPncI1USU6JRWK=
KU-19-19 M{H3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEeyRZhKSzVyPU[uNFE4OzFizszN MoD0V2FPT0WU
CFPAC-1 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkeyTWM2OD14LkC0OFQ{KM7:TR?= MlfpV2FPT0WU
LoVo NWfONZpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO4NZFKSzVyPU[uNFUxPjNizszN MkXLV2FPT0WU
8505C MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\W[mlEPTB;Nj6wO|U4OyEQvF2= MlLIV2FPT0WU
GMS-10 M37rVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPiO4tKSzVyPU[uNVUxODJizszN Ml;1V2FPT0WU
Ca9-22 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\sTWM2OD14LkG2O|Eh|ryP MoDTV2FPT0WU
DOK NYDBfXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLNTWM2OD14LkKyNFczKM7:TR?= M3vjdnNCVkeHUh?=
FADU Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrLR2I6UUN3ME22MlI3ODN7IN88US=> M4HZRnNCVkeHUh?=
BxPC-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPUbmRKSzVyPU[uNlc{OiEQvF2= M{S0dHNCVkeHUh?=
CAL-33 NHLtfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\qVmlEPTB;Nj6yPVIxOSEQvF2= MknmV2FPT0WU
SHP-77 M1H0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nMOmlEPTB;Nj6zNVUyOiEQvF2= MVvTRW5ITVJ?
LXF-289 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZwM{O0OVUh|ryP MofFV2FPT0WU
GB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPpVIVRUUN3ME22MlM5OiEQvF2= NX\YUm92W0GQR1XS
KS-1 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fP[mlEPTB;Nj6zPFQ1PyEQvF2= Mm\0V2FPT0WU
D-502MG MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlq0TWM2OD14LkSyN|c3KM7:TR?= MYHTRW5ITVJ?
LAN-6 M2TROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnXblIyUUN3ME22MlUyODJ|IN88US=> MVLTRW5ITVJ?
H-EMC-SS NHS0VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTZwNU[xOFch|ryP NGTUW5NUSU6JRWK=
LC-2-ad NF7VVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLCc41xUUN3ME22MlYxODd4IN88US=> M1z4fXNCVkeHUh?=
NCI-H1693 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTZwNkKyNVUh|ryP Ml3XV2FPT0WU
SK-N-FI NYrkdHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDe2lEPTB;Nj63OVA1PCEQvF2= NXPQe3drW0GQR1XS
D-423MG NUWxUmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvlTnIzUUN3ME22Mlc3OTF5IN88US=> MnO3V2FPT0WU
KNS-42 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfQc4pKSzVyPU[uO|gyQTdizszN MlLvV2FPT0WU
GCT NIDqTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTZwOUO4JO69VQ>? NUjHfohtW0GQR1XS
DSH1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke1TWM2OD15LkC2N|Mh|ryP NYDITFRuW0GQR1XS
D-247MG M2\5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnyT|ZKSzVyPUeuNFc5QDFizszN M3yySnNCVkeHUh?=
NCI-SNU-5 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX0cWxvUUN3ME23MlE5OzdzIN88US=> MVzTRW5ITVJ?
TE-6 NET6NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHuTZRKSzVyPUeuNlA3ODFizszN MUfTRW5ITVJ?
NOMO-1 M1f1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD15LkKyNVI4KM7:TR?= M3rPW3NCVkeHUh?=
NB17 NUTkRYxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;jTWM2OD15LkOwN|A6KM7:TR?= M4LMSnNCVkeHUh?=
EW-22 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwM{SzOFgh|ryP NYL3bFB5W0GQR1XS
EW-13 NX7mbm5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojwTWM2OD15LkO1NVYzKM7:TR?= MXXTRW5ITVJ?
DOHH-2 NE\FSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwNESwNkDPxE1? M3i3Z3NCVkeHUh?=
TGBC1TKB NVPqRW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHNUJlKSzVyPUeuOFk5QTlizszN MoLuV2FPT0WU
GR-ST NIfKNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnTW4FKSzVyPUeuOVI2QTRizszN M3:5fnNCVkeHUh?=
KYSE-520 M3Gy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPyTWM2OD15LkW1OVE2KM7:TR?= M3rRe3NCVkeHUh?=
CAPAN-1 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTdwNUm1NUDPxE1? Ml3BV2FPT0WU
HCE-4 M4TOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6TWM2OD15Lk[yNlc6KM7:TR?= NWTlR5ZkW0GQR1XS
MLMA M3vKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TzXWlEPTB;Nz62Nlk2PyEQvF2= M3mzOHNCVkeHUh?=
HT-144 NHzVZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD15Lk[1N|Y5KM7:TR?= NFnIPVFUSU6JRWK=
KYSE-180 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwN{GxOlkh|ryP MUHTRW5ITVJ?
TE-5 NWDpcZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[2[VYzUUN3ME23Mlk2QTdzIN88US=> NUj3UJV[W0GQR1XS
IGROV-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTdwOUi1OVEh|ryP M{K2cnNCVkeHUh?=
NCI-H1581 NWn5fpdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7penZKSzVyPUiuNFEzKM7:TR?= M2j6e3NCVkeHUh?=
SW1990 NETWS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThwMES2OVkh|ryP MlXCV2FPT0WU
EFM-19 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nRfmlEPTB;OD6wPFU1PSEQvF2= M1;YU3NCVkeHUh?=
OGR-1 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K1eGlEPTB;OD60N|AzOyEQvF2= NYC2TXBYW0GQR1XS
U-118-MG NXnu[VF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TVPGlEPTB;OD60N|Q3OyEQvF2= NEjDdG1USU6JRWK=
SK-OV-3 M1;EUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRThwNE[3OlUh|ryP Mm\wV2FPT0WU
KNS-62 M2L3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQ[Y9EUUN3ME24MlUyPzZzIN88US=> MYnTRW5ITVJ?
GOTO M13QcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojvTWM2OD16LkW3OlM2KM7:TR?= NFztUmlUSU6JRWK=
8305C M1TIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRThwN{C0PFQh|ryP MVHTRW5ITVJ?
RPMI-2650 NHvIPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrPT5p7UUN3ME24MlcyQTV3IN88US=> MYfTRW5ITVJ?
NEC8 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HEcGlEPTB;OD63OFMxPyEQvF2= M1XtOXNCVkeHUh?=
KYSE-450 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPTeZJYUUN3ME24Mlg3PTR6IN88US=> MWXTRW5ITVJ?
RMG-I NG\Wc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFizO|BKSzVyPUmuNVQxPThizszN MXHTRW5ITVJ?
CAKI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjsW2pKSzVyPUmuN|E6PzlizszN NXvFSZZyW0GQR1XS
KYSE-510 NUfHcXBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES3NIhKSzVyPUmuN|U4PzhizszN M3SxdHNCVkeHUh?=
A4-Fuk MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPuUYNKSzVyPUmuN|Y4ODFizszN NYLiZ2dGW0GQR1XS
AN3-CA M2DyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\oSWlEPTB;OT60OVQ1PCEQvF2= NHzWXIZUSU6JRWK=
SK-N-DZ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO5TWM2OD17LkeyPFQ6KM7:TR?= MWnTRW5ITVJ?
HSC-2 NV\ZdZc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmc|IyUUN3ME25Mlc3PjJ7IN88US=> MW\TRW5ITVJ?
EW-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPwW2VKSzVyPUmuO|k{PjlizszN MoXjV2FPT0WU
D-566MG M{nNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTlwOEO2OlQh|ryP NUnCUWNYW0GQR1XS
COLO-792 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGxO4hqUUN3ME25Mlk5PzR4IN88US=> NEHPRVVUSU6JRWK=
TE-10 NGPnc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{ewRWlEPTB;MUCuNFM6PiEQvF2= NX\HeXBOW0GQR1XS
NCI-H650 M{TZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXDWlg1UUN3ME2xNE41Ojh4IN88US=> M13VcHNCVkeHUh?=
U-266 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnYUpVpUUN3ME2xNE41PTVizszN NXLEVVdGW0GQR1XS
Detroit562 NEf3V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFzLkC1NVUh|ryP NUn6T|ViW0GQR1XS
NH-12 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTFzLkG0OFYh|ryP NVnmW2VSW0GQR1XS
CO-314 NGDOV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGx[4ZKSzVyPUGxMlI5PDJizszN MnXZV2FPT0WU
IST-MEL1 M4fKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxblBHUUN3ME2xNU42OzJ|IN88US=> MnnZV2FPT0WU
KNS-81-FD MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFzLkW1Nlch|ryP NInDNYNUSU6JRWK=
SW1463 NFflU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rTeGlEPTB;MUGuOVk5QSEQvF2= NWK2XJNCW0GQR1XS
NCI-H23 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fVVGlEPTB;MUGuOlU2OiEQvF2= MYXTRW5ITVJ?
SK-MEL-2 NGT2N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLiTWM2OD1zMT63NVk4KM7:TR?= M{W3fnNCVkeHUh?=
NB13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj6[JZxUUN3ME2xNk4yPDl3IN88US=> NYqzV2JjW0GQR1XS
Daoy NH3CS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfUWXQ5UUN3ME2xNk4zQDV4IN88US=> MWrTRW5ITVJ?
NCI-H1623 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF{LkO4NFEh|ryP M4mx[HNCVkeHUh?=
NMC-G1 M4qwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF{LkexO{DPxE1? M1PL[3NCVkeHUh?=
DK-MG NXLxPXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT4WWpqUUN3ME2xNk46PDh{IN88US=> NFztWJBUSU6JRWK=
TCCSUP NF\ZZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrOTWM2OD1zMz6xNlg1KM7:TR?= MWrTRW5ITVJ?
SCC-15 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C2d2lEPTB;MUOuNlY2OSEQvF2= NEW0SnpUSU6JRWK=
NOS-1 NV;6TZljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\PcGlEPTB;MUOuNlg6OyEQvF2= Mn7vV2FPT0WU
RH-1 NV[we5h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\BfohNUUN3ME2xN{4{ODN5IN88US=> NWe0SWVSW0GQR1XS
SK-MEL-3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjTWM2OD1zMz6zO|I5KM7:TR?= Mn73V2FPT0WU
NB5 NX3OUHI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3UTWM2OD1zMz60NFY4KM7:TR?= NIHKe4lUSU6JRWK=
SNU-387 NV\INGVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPSTWM2OD1zMz61NFczKM7:TR?= NXLGNpNPW0GQR1XS
CAL-120 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF|Lk[3NVgh|ryP NXTtdlRzW0GQR1XS
Mo-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv3fmdKSzVyPUGzMlcxPyEQvF2= NVvmXopmW0GQR1XS
LNCaP-Clone-FGC M3nQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HCb2lEPTB;MUOuO|k6OiEQvF2= MXLTRW5ITVJ?
CAN MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i3VWlEPTB;MUSuNFI5QCEQvF2= NYXB[5lyW0GQR1XS
SK-MEL-30 M1Ly[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF2LkC2N{DPxE1? MYrTRW5ITVJ?
COLO-678 NVHlXHJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF2LkC4NlIh|ryP M1ztNHNCVkeHUh?=
SCC-9 NEnhN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\vWGlEPTB;MUSuNVAzOSEQvF2= MknuV2FPT0WU
KINGS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fENGlEPTB;MUSuNVQxOiEQvF2= MofUV2FPT0WU
SL-513 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu2NVZYUUN3ME2xOE4yQDdizszN NITpV3hUSU6JRWK=
HLE M3PlfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTPTWM2OD1zND6zPFUzKM7:TR?= M37TO3NCVkeHUh?=
SW1573 NIPjTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLSTWM2OD1zND60OFM2KM7:TR?= NV3ZVm1CW0GQR1XS
KYSE-140 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDxTXhFUUN3ME2xOE43OzJ5IN88US=> NVvmN5V5W0GQR1XS
SK-PN-DW NU\ibJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF2LkiwNFEh|ryP MkfLV2FPT0WU
A253 NYO2Wo86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3se5FKSzVyPUG1MlA3OjVizszN Ml7tV2FPT0WU
CAL-12T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4POO2lEPTB;MUWuOFY3OiEQvF2= NEmxcIlUSU6JRWK=
COLO-679 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz6TWM2OD1zNT63Olg{KM7:TR?= NX3RSmVbW0GQR1XS
UACC-257 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH1PFhKSzVyPUG2MlEzODFizszN NX;HSYNwW0GQR1XS
U-87-MG M{fvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjNmlEPTB;MU[uN|UzOyEQvF2= M1jUWnNCVkeHUh?=
HCC1806 NXHIWVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVUWNvUUN3ME2xOk44ODdzIN88US=> M1jHcXNCVkeHUh?=
NCI-H2170 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvpTWM2OD1zNz6yOFQ5KM7:TR?= M{nhZ3NCVkeHUh?=
AGS NY\kWXBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTFRnhKSzVyPUG3MlM5ODhizszN NInvbpFUSU6JRWK=
MEL-HO NIHNUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfBTWM2OD1zNz63OVA{KM7:TR?= NH:yfnNUSU6JRWK=
SW48 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tld2lEPTB;MUeuO|cyPiEQvF2= MkHpV2FPT0WU
HuP-T4 NXLocYtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW2fmd{UUN3ME2xPE4xOjB4IN88US=> NGntb4VUSU6JRWK=
NCI-H720 M4jGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS4UZVKSzVyPUG4MlE1ODJizszN MUHTRW5ITVJ?
RCC10RGB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLLTWM2OD1zOD6xOlk4KM7:TR?= MUTTRW5ITVJ?
HD-MY-Z Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF6LkKyOVQh|ryP MUnTRW5ITVJ?
A427 NWq3cnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULIRnZVUUN3ME2xPE42ODl2IN88US=> M2LHZ3NCVkeHUh?=
HCC2998 NWDu[GJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDOcXVxUUN3ME2xPE43ODVzIN88US=> NET4eZBUSU6JRWK=
EPLC-272H M{C2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXOVpdKSzVyPUG5MlA1OzRizszN NGrqS|NUSU6JRWK=
C32 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDzTWM2OD1zOT6wOFUh|ryP M1fU[3NCVkeHUh?=
UMC-11 NV7P[4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X0ZmlEPTB;MUmuNlEzOyEQvF2= NF7qXXdUSU6JRWK=
CaR-1 M3\5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;yTWM2OD1zOT62PFA1KM7:TR?= MnvJV2FPT0WU
KYSE-410 NFPyfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXizW2xtUUN3ME2xPU46OTN7IN88US=> MkPaV2FPT0WU
HuCCT1 M{HWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJyLk[yPVQh|ryP MV;TRW5ITVJ?
LB996-RCC NWf1SnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\5WYc1UUN3ME2yNE44OTZ6IN88US=> Ml3xV2FPT0WU
KYSE-70 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3NTWM2OD1{MD64NFU6KM7:TR?= MUPTRW5ITVJ?
CAL-72 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MornTWM2OD1{MD65NVUh|ryP NGHVXpFUSU6JRWK=
Capan-2 NInUd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTKTWM2OD1{MT6wOFE{KM7:TR?= NHLZUGdUSU6JRWK=
PANC-08-13 NYH4XXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmryTWM2OD1{MT6yOVE2KM7:TR?= NHy1dZJUSU6JRWK=
SBC-1 NILnR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrK[JFKSzVyPUKxMlMxQDFizszN MnLNV2FPT0WU
MFM-223 NEDiUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jpc2lEPTB;MkGuN|M1OiEQvF2= MXfTRW5ITVJ?
BB49-HNC MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJzLkW3NVYh|ryP MVjTRW5ITVJ?
SH-4 M173Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\TWWlEPTB;MkGuOlYyQCEQvF2= MYTTRW5ITVJ?
HuO9 NXTtfohbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD1{MT65PFI2KM7:TR?= MmDJV2FPT0WU
AM-38 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\TbYw{UUN3ME2yNk4xPDh3IN88US=> MXnTRW5ITVJ?
A431 M1Ps[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDNTWM2OD1{Mz6yNVE6KM7:TR?= MXnTRW5ITVJ?
YAPC Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ|LkK2OVEh|ryP NFLWcVNUSU6JRWK=
LU-139 M3W3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L3c2lEPTB;MkOuOFgxQSEQvF2= MojUV2FPT0WU
HEC-1 NUP1NFRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWy[FJKSzVyPUKzMlQ6OzdizszN M3fZSHNCVkeHUh?=
SCC-25 NWXyd4dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJ2LkOwNFYh|ryP MUTTRW5ITVJ?
HT-29 NGi5S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW4NIJKSzVyPUK0MlM5OjNizszN MYHTRW5ITVJ?
PC-14 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[wfZRtUUN3ME2yOE43PTdzIN88US=> MoriV2FPT0WU
Calu-6 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\YOmlEPTB;MkWuOVA4OSEQvF2= MVTTRW5ITVJ?
SJRH30 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5bHI4UUN3ME2yOU43PDl4IN88US=> NGPZcWFUSU6JRWK=
ChaGo-K-1 NXjnOGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYG5R3dSUUN3ME2yOk4yPjJ7IN88US=> MVjTRW5ITVJ?
IA-LM Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\nTWM2OD1{Nj6zOlQ2KM7:TR?= MnLKV2FPT0WU
GP5d MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2fWFKSzVyPUK2MlQ1QTFizszN NGPteXlUSU6JRWK=
NCI-H2291 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX3bFdRUUN3ME2yOk43PTRzIN88US=> NIH6b|lUSU6JRWK=
BALL-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPHTWM2OD1{Nj65N|k4KM7:TR?= NWm0VVhSW0GQR1XS
HCC1954 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1niemlEPTB;Mk[uPVgxQCEQvF2= MUHTRW5ITVJ?
NCI-H2452 M4\QdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXmTWM2OD1{Nz60NVY{KM7:TR?= Mlf1V2FPT0WU
LU-99A M3PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe0VmFTUUN3ME2yO{42PTh{IN88US=> MYPTRW5ITVJ?
NTERA-S-cl-D1 M{SxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzSXZJKSzVyPUK3MlczQTlizszN NILuNpdUSU6JRWK=
PANC-10-05 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4roVmlEPTB;MkeuO|c4PSEQvF2= NEHzNo1USU6JRWK=
NCI-H2405 NYLCRWlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X3T2lEPTB;MkeuPVM5PyEQvF2= NIPoVWxUSU6JRWK=
MDA-MB-415 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLtTWM2OD1{OD60NVM4KM7:TR?= MnHKV2FPT0WU
NCI-H2342 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLjOm5tUUN3ME2yPE42OjhzIN88US=> M3roUHNCVkeHUh?=
TGBC24TKB MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fQfWlEPTB;MkiuO|EyPyEQvF2= M{TWV3NCVkeHUh?=
LU-134-A MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ6LkmyOlEh|ryP M2XYUnNCVkeHUh?=
SCC-4 NGPiWZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XqO2lEPTB;M{GuNFQ6PCEQvF2= M4LMcHNCVkeHUh?=
Saos-2 NXjVTWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3pe4J1UUN3ME2zNU46OzB4IN88US=> MXvTRW5ITVJ?
RERF-LC-MS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTNZ|JKSzVyPUOyMlgzOzFizszN NW\ZcJh[W0GQR1XS
M14 NWHOWHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN{Lkm3OlQh|ryP MmXxV2FPT0WU
HPAF-II NHPV[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GyPGlEPTB;M{OuOVAyOSEQvF2= NYDNXVREW0GQR1XS
NCI-H1755 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fOWmlEPTB;M{SuN|MxPSEQvF2= Mnn2V2FPT0WU
D-392MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXTTWM2OD1|NT64Olc1KM7:TR?= MXXTRW5ITVJ?
A704 MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDETWM2OD1|Nj6wOFI4KM7:TR?= NH;DNVFUSU6JRWK=
CP50-MEL-B NEDHS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD1|Nj6xPVEyKM7:TR?= MlzUV2FPT0WU
EW-18 NH3LNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTN4LkS1NkDPxE1? NUm0Uop3W0GQR1XS
WM-115 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPmUpVKSzVyPUO2MlgxQTlizszN NWKzbGlDW0GQR1XS
LU-65 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzJTWM2OD1|Nz6xOFE4KM7:TR?= MUjTRW5ITVJ?
NCI-H1563 NWqxbFk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof0TWM2OD1|Nz6yOFg1KM7:TR?= NFizTFBUSU6JRWK=
DBTRG-05MG M{\NZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN6LkC2PVEh|ryP NXnDS2VyW0GQR1XS
NCI-H630 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPR[HFKSzVyPUO4MlQ4OTRizszN M1\INXNCVkeHUh?=
NCI-H1155 M1\tWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTN7LkK0NkDPxE1? M3i2XHNCVkeHUh?=
OVACR-3 NHXxV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW3W|hKSzVyPUO5MlkyQTVizszN NYP1[lU2W0GQR1XS
OAW-42 NEjZWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXCTWM2OD12MD60NlU5KM7:TR?= MXjTRW5ITVJ?
JVM-2 NYXvZVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXv5OZF{UUN3ME20NU4zPDF3IN88US=> MVrTRW5ITVJ?
C3A M13TcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrtNVZKSzVyPUSxMlM1PDdizszN MkC0V2FPT0WU
HT55 NGPZWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\qPWlEPTB;NEKuNlg1OSEQvF2= M321S3NCVkeHUh?=
OVCAR-4 NX\kXVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j5UmlEPTB;NEKuNlk4PCEQvF2= NF;RfGZUSU6JRWK=
MEG-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOxdFhFUUN3ME20Nk41PjF4IN88US=> M1ewOHNCVkeHUh?=
NCI-H82 M{LiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHl[49KSzVyPUSzMlk5QTJizszN NVTLWYU6W0GQR1XS
JEG-3 NGToSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXucIQ{UUN3ME20OE46PDdizszN M{\oUnNCVkeHUh?=
BPH-1 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnqSXZEUUN3ME20Ok4{QTl6IN88US=> M37nXnNCVkeHUh?=
MPP-89 NH[3RppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzjOpJKSzVyPUS3MlI5QThizszN NWnmfmM2W0GQR1XS
ALL-PO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfrfFQzUUN3ME20O{41OTh6IN88US=> NVKyUZE2W0GQR1XS
HT MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWTWM2OD12Nz60PVIh|ryP MWXTRW5ITVJ?
NCI-H2347 NIrZXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M373NmlEPTB;NEiuNFcyPSEQvF2= NUHVW5Q2W0GQR1XS
A2780 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nBd2lEPTB;NEmuOFIzQCEQvF2= Mme1V2FPT0WU
KARPAS-299 M33NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTR7LkWxNVkh|ryP M{TMWXNCVkeHUh?=
NCI-H1651 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD12OT64PFIyKM7:TR?= M{HpTHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; 

PubMed: 30300583     


Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells.

pRb(S807, 811) / CDK4 / CDK6 / PARP; 

PubMed: 28453226     


Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. 

LC3-I / LC3-II; 

PubMed: 28453226     


Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. 

pAMPKα(T172) / pULK1(S317); 

PubMed: 28453226     


Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. 

SMAD2 (pS255); 

PubMed: 30343527     


T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.

30300583 28453226 30343527
Growth inhibition assay
Cell viability; 

PubMed: 29670090     


Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.

29670090
Immunofluorescence
SAHF/ATRX; 

PubMed: 26988987     


DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. 

LC3B; 

PubMed: 28453226     


LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).

26988987 28453226
ELISA
PGE2; 

PubMed: 26540629     


The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.

26540629
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

- Collapse

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

- Collapse
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Drug: Palbociclib|Other: locoregional treatment Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer October 15 2019 Not Applicable
NCT03900884 Not yet recruiting Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole Breast Neoplasm Female Peter MacCallum Cancer Centre Australia September 2019 Phase 1
NCT03844997 Recruiting Drug: Palcociclib|Drug: CPX-351 Acute Myeloid Leukemia|AML Aziz Nazha|Case Comprehensive Cancer Center May 31 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID